Cover Image
市場調查報告書

代謝體學:技術和全球市場

Metabolomics: Technologies and Global Markets

出版商 BCC Research 商品編碼 261643
出版日期 內容資訊 英文 202 Pages
訂單完成後即時交付
價格
Back to Top
代謝體學:技術和全球市場 Metabolomics: Technologies and Global Markets
出版日期: 2015年11月30日 內容資訊: 英文 202 Pages
簡介

全球代謝體學市場,2014年成為59億美元規模,到2015年達68億美元,至2020年達125億美元,在預測期間中預計顯示13.0%的年複合成長率。

本報告提供全球代謝體學市場及技術的相關調查、代謝體學研究領域的商業性可能性、市場趨勢的實際成果資料和今後的年複合成長率預測、代謝組&代謝產物&代謝體學vs.代謝組學定義、代謝體學的概念的方法、代謝體學市場主要結構 (市場區隔、主要應用領域、市場參與企業) 調查、代謝體學的分離技術 (氣相層析法、毛細管電泳法、HPLC) 、專利分析及主要企業簡介等彙整,為您概述為以下內容。

第1章 簡介

第2章 摘要

第3章 代謝體學概要

  • 代謝產物
  • 代謝體學
  • 代謝體學的歷史
  • 代謝體學的基本
  • 異化途徑、融化途徑
  • 腺苷三磷酸 (ATP)
  • 酵素所扮演的角色
  • 回饋阻礙
  • 粒腺體位置
  • 氧化、還原反應
  • 脫水本源酵素
  • 電子傳達鎖鏈
  • 氧化的、基材層級的磷酸化
  • 糖解
  • 克雷伯氏環路
  • 乙醯輔酶A
  • 電子傳達:黃素蛋白,細胞色素
  • TCA循環
  • Adenosine3磷酸 (ATP) 合成
  • 發酵
  • 應用
  • 課題
  • 分析技術
  • 效能促進要素
  • 市場2次區分、其他

第4章 代謝體學分析流程、設備

  • 代謝體學的流程階段
  • 代謝體學分析的次序
  • 樣品製作、開採所採用的設備
  • 分離、檢測產品
  • 分離
  • 檢測
  • 聯用的方法
  • 氣相層析法質譜分析
  • 液體層析法質譜分析
  • 毛細管電泳法質譜分析
  • 新的檢測技術
  • 分析設備市場
  • 代謝體學市場上所採用的分析設備

第5章 化驗的零組件及代謝體學的套件

  • 標的代謝體學
  • 本章的調查範圍
  • 化驗概要
  • 化驗、化驗套件的背景
  • 生化化驗
  • 化驗的商業性討論事項
  • 化驗檢測概要
  • 細胞分析的商業性情形
  • 代謝體學研究所採用的主要小品文的類型
  • 代謝所採用的化驗
  • 氧化、還原反應
  • 藥物研發的利用
  • 工具、技術
  • 新的分析工具
  • 引進趨勢
  • 相關應用的化驗
  • 細胞毒性:主要的分類
  • 細胞生存、生存的代謝化驗
  • 細胞死的化驗
  • 細胞增生抑制性或長期的影響的化驗
  • 多化驗、其他

第6章 代謝體學的生物資訊學

  • 概要
  • 生物資訊學過程
  • 資料結構分析、處理
  • 資料削減、整合
  • 資料建模
  • 資料虛擬化
  • 資料庫策展、管理
  • 代謝體學的公共資金
  • 商業市場結構
  • 自家公司開發軟體的企業
  • 市場

第7章 臨床生物標記

  • 概要
  • 生物標記的課題
  • 來自蛋白質體學的進步
  • 代謝體學的優點
  • 應用引進
  • 主要臨床應用
  • 藥理基因學
  • 肝臟酵素
  • Clopidogrel
  • 人類白細胞抗原B
  • 卡馬西平
  • AZATHIOPRINE
  • 心理健康
  • 血清素
  • 兒茶酚甲基轉移酵素
  • 藥理動態、藥物動態遺傳基因
  • 商業案例
  • 課題、未來的方向性
  • 癌症
  • 心血管、代謝疾病
  • 肝疾病
  • 商業上檢討事項

第8章 企業簡介

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO055B

REPORT HIGHLIGHTS

The global metabolomic market totaled $5.9 billion in 2014 and should total $6.8 billion in 2015 and $12.5 billion by 2020, registering a compound annual growth rate (CAGR) of 13.0%.

This report provides:

  • An overview of the commercial potential of the metabolomics research field, the systematic study of the unique chemical fingerprints that cellular processes leaves behind
  • Analyses of global market trends, with data from 2014, estimates for 2015 and projections of compound annual growth rates (CAGRs) through 2020
  • Definitions of metabolome, metabolites, and metabolomics vs. metabonomics
  • Discussion of the conceptual approach in metabolomics: target analysis, metabolite profiling, metabolomics, metabolic fingerprinting
  • Examination of the main structure of the metabolomics market: segments, key application areas, and market participants
  • Separation techniques for metabolomics: gas chromatography, capillary electrophoresis, and high-performance liquid chromatography (HPLC)
  • Patent analysis
  • Company profiles of major players in the field

SCOPE OF REPORT

The scope of the report encompasses the major metabolomic technology types that have been used, as well as the major applications being developed by industry, academic researchers and their commercialization offices, and government agencies. It analyzes current market status, examines future market drivers and presents forecasts of growth over the next five years. Technology developments, including the latest trends, are discussed. Other influential factors such as screening strategies for pharmaceuticals have also been included.

ANALYST'S CREDENTIALS

Robert G. Hunter has more than 20 years of experience in life sciences as an analyst, business development executive, project manager and management consultant for business processes, organizational development and systems implementation. His recent BCC Research reports include BIO140A 3D Cell Culture: Technologies and Global Markets, and PHM017E In Vitro Toxicology, which also covered in silico applications and the status of predictive medicine. His studies have included multiple stem cell lines for true genetic diversity and proteomic biomarkers for cancer via label-free imaging. He is an early investor in a company using stem cells for in vitro screening of pharmaceutical compounds.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL METABOLOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL METABOLOMIC MARKET BY APPLICATION, 2014-2020 ($ MILLIONS)

CHAPTER 3 - OVERVIEW OF METABOLOMICS

  • METABOLITES
  • METABOLOMICS
  • METABOLOMIC HISTORY
    • TABLE 1: HUMAN METABOLOME PROJECT AND DATABASE, 2006-2013
  • METABOLISM BASICS
  • CATABOLIC AND ANABOLIC PATHWAYS
    • TABLE 2: CELLULAR RESPIRATION STAGES
  • ADENOSINE TRIPHOSPHATE
  • ENZYME ROLE
    • TABLE 3: FACTORS IMPACTING ENZYME ACTIVITY
  • FEEDBACK INHIBITION
  • LOCATED IN MITOCHONDRIA
  • OXIDATION AND REDUCTION REACTIONS
  • DEHYDROGENASES
  • ELECTRON TRANSPORT CHAIN
  • OXIDATIVE AND SUBSTRATE-LEVEL PHOSPHORYLATION
  • GLYCOLYSIS
  • KREBS CYCLE
  • ACETYL COA
  • NADH AND FADH2 DONATE ELECTRONS
  • ELECTRON TRANSPORTERS: FLAVOPROTEIN AND CYTOCHROMES
  • TRICARBOXYLIC ACID CYCLE
  • ADENOSINE TRIPHOSPHATE SYNTHESIS
  • FERMENTATION
  • FOOD TO ENERGY
  • LIPID PROCESSING
  • FATTY ACID BETA-OXIDATION IN THE HEART
  • KETOSIS
    • BENEFITS
  • METABOLOMES
    • LARGE BOWEL MICROFLORA
    • URINE METABOLOME
    • FOOD METABOLOME
  • LIPIDOMICS
  • FLUXOMICS
  • APPLICATIONS
  • CHALLENGES
  • ANALYTICAL TECHNOLOGIES
  • PERFORMANCE DRIVERS
    • LIMITS OF DETECTION
    • TARGETED VERSUS UNTARGETED APPROACHES
    • TARGETED ANALYSIS
    • METABOLITE PROFILING
    • METABOLIC FINGERPRINTING
    • UNTARGETED APPROACHES
  • MARKET SUB-SEGMENTS
    • TABLE 4: PUBLICATIONS USING KEYWORD METABOLOMICS IN THE SEARCH, 2002-2014 (TOTAL PER YEAR)
    • FIGURE 1: PUBLICATIONS USING KEYWORD METABOLOMICS IN THE SEARCH, 2002-2014 (TOTAL PER YEAR)

CHAPTER 4 - METABOLOMIC ANALYTICAL PROCESSES AND INSTRUMENTS

  • METABOLOMIC PROCESS STEPS
    • TABLE 5: TYPICAL ANALYTICAL METRABOLOMIC PROCESS STEPS
  • METABOLOMIC ANALYSIS PROCEDURES
    • SAMPLE PREPARATION
    • EXTRACTION
    • DERIVATIZATION
    • SEPARATION AND DETECTION
    • DATA ANALYSIS
  • EQUIPMENT USED IN SAMPLE PREPARATION AND EXTRACTION
  • SEPARATION AND DETECTION PRODUCTS
  • SEPARATION
    • CHROMATOGRAPHY
      • High-Performance Liquid Chromatography
      • Gas Chromatography
    • CAPILLARY ELECTROPHORESIS
    • SEPARATION EQUIPMENT MARKET
    • SUPPLIERS
      • TABLE 6: MAIN SEPARATION INSTRUMENT SUPPLIERS
  • DETECTION
    • MASS SPECTROMETRY
      • TABLE 7: MAIN MASS SPECTROSCOPY SUPPLIERS FOR LIFE SCIENCES
      • Direct Injection
      • Mass Spectrometry Imaging
      • Mass Spectrometry Types
      • Ion Trap
      • Quadrupole
      • Time-of-Flight Mass Spectrometers
        • TABLE 8: LEADING MASS SPECTROSCOPY SYSTEMS
    • NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
    • NUCLEAR MAGNETIC RESONANCE VERSUS MASS SPECTROSCOPY
  • HYPHENATED APPROACHES
  • GAS CHROMATOGRAPHY-MASS SPECTROMETRY
    • SINGLE QUADRUPOLE INSTRUMENTS
    • TIME OF FLIGHT INSTRUMENTS
  • LIQUID CHROMATOGRAPHY MASS SPECTROSCOPY
  • CAPILLARY ELECTROPHORESIS-MASS SPECTROSCOPY
    • TABLE 9: COMMON HYPHENATED PLATFORMS IN METABOLOMIC RESEARCH
  • EMERGING DETECTION TECHNOLOGIES
    • MATRIX-ASSISTED LASER DESORPTION/IONIZATION
    • FOURIER TRANSFORM MASS SPECTROSCOPY
    • FOLDED FLIGHT PATH
    • COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY TIME-OF-FLIGHT MASS SPECTROSCOPY
    • MULTIPLE REACTION MONITORING
      • Targeted Untargeted Approach
      • Capillary Electrophoresis Mass Spectroscopy with Sheathless Interfaces
    • PROTEOMIC USE
      • Proteomics
    • METALLOMICS OVERVIEW
      • Tools Used in Metallomics
  • ANALYTICAL EQUIPMENT MARKET
    • TABLE 10: GLOBAL MASS SPECTROMETRY MARKET, THROUGH 2017 ($ BILLIONS)
  • ANALYTICAL EQUIPMENT USED IN THE METABOLOMIC MARKET
    • TABLE 11: GLOBAL ANALYTICAL EQUIPMENT USED IN THE METABOLOMIC MARKET, THROUGH 2020 ($ MILLIONS)

CHAPTER 5 - ASSAY COMPONENTS AND KITS FOR METABOLOMICS

  • TARGETED METABOLOMICS
  • CHAPTER SCOPE
  • ASSAYS OVERVIEW
  • BACKGROUND ON ASSAYS AND ASSAY KITS
  • BIOCHEMICAL ASSAYS
    • CELL-BASED ASSAYS
    • CELL-BASED ASSAY TYPES
    • ASSAY READOUT: OVERVIEW OF DETECTION
    • CELL TYPES USED IN CELL-BASED ASSAYS
      • Immortalized Cell Lines and Primary Cells for Screening
      • Stem Cells at Scale
        • Cellular Dynamics Inc.
  • ASSAY COMMERCIAL CONSIDERATIONS
    • MICROPLATE PLATFORM
    • STANDARDS SETTING
    • CONTINUOUS INNOVATION
    • MICROPLATE READERS
  • ASSAY DETECTION OVERVIEW
    • FLUORESCENCE AS A DRIVER
    • HIGH-CONTENT SCREENING
      • Imaging Advances
      • Future Vision for High-Content Screening
        • TABLE 12: HIGH-CONTENT SCREENING SUPPLIERS AND KEY ATTRIBUTES
    • LABEL-FREE PLATFORMS
      • TABLE 13: LABEL-FREE TECHNOLOGIES AND SUPPLIERS
    • ELECTROPHYSIOLOGY
  • COMMERCIAL LANDSCAPE OF CELL-BASED ASSAYS
  • MAJOR ASSAYS TYPES USED IN METABOLOMICS RESEARCH
    • OTHER TYPES
      • TABLE 14: OTHER ASSAY TYPES USED IN METABOLOMIC RESEARCH
    • MAIN CELL METABOLISM ASSAY APPLICATIONS
      • TABLE 15: MAIN CELL METABOLISM ASSAY APPLICATIONS
  • ASSAYS USED IN METABOLISM
    • ADENOSINE TRIPHOSPHATE
    • ENZYME ROLE
      • Phosphofructokinase
      • 2-Phosphoglycerate
  • OXIDATION AND REDUCTION REACTIONS
    • DEHYDROGENASES
    • ELECTRON TRANSPORT CHAIN
    • OXIDATIVE AND SUBSTRATE-LEVEL PHOSPHORYLATION
    • GLYCOLYSIS
    • KREBS CYCLE
    • METABOLITE ASSAYS
    • ACETYL COA
    • NICOTINAMIDE ADENINE DINUCLEOTIDE AND NADH FADH2
      • Nicotinamide Adenine Dinucleotide Assays
    • OXIDATIVE STRESS ASSAYS
      • TABLE 16: ASSAYS COMMONLY USED IN METABOLOMICS
  • DRUG DISCOVERY USES
    • DRUG DISCOVERY DRIVERS
    • MITOCHONDRIA OPPORTUNITY
    • MITOCHONDRIAL FUNCTION AND CELL METABOLISM
    • MITOCHONDRIAL TOXICITY
      • TABLE 17: MAJOR CATEGORIES OF ASSAYS USED IN METABOLOMICS FOR DRUG DISCOVERY
  • TOOLS AND TECHNOLOGIES
    • TRADITIONAL METHODS
    • OTHER TECHNOLOGIES
  • NEW ANALYSIS TOOLS
    • BIOMARKER ASSAYS
    • FLUORESCENT DYES
    • BIOSENSING TECHNOLOGY
  • ADOPTION TRENDS
    • CANCER
    • OXYGEN CONSUMPTION ASSAY
    • SEAHORSE METABOLIC ANALYZERS
  • ASSAYS IN RELATED APPLICATIONS
    • TABLE 18: OTHER ASSAYS COMMONLY USED ALONGSIDE METABOLOMIC ASSAYS
  • CYTOTOXICITY: A MAJOR CATEGORY
    • CYTOTOXIC AND/OR CYTOSTATIC IMPACTS
    • SCREENING STRATEGIES
  • PERMEABILITY ASSAYS FOR CELL VIABILITY AND SURVIVAL
    • LACTATE DEHYDROGENASE ENZYME RELEASE ASSAYS
    • DYE UPTAKE
    • NEUTRAL RED UPTAKE FOR CELL SURVIVAL ASSAYS
    • ADVANTAGES AND DISADVANTAGES
  • METABOLIC ASSAYS FOR CELL VIABILITY AND SURVIVAL
    • MTT ASSAY
    • ADENOSINE TRIPHOSPHATE ASSAY
    • DISADVANTAGES OF METABOLIC ASSAYS
    • FLUOROMETRIC APPROACHES
    • ALTERED CELL ADHESION
  • ASSAYS FOR CELL DEATH
    • APOPTOSIS VERSUS NECROSIS
    • CASPASE ACTIVATION
    • MEMBRANE RESIDUES
    • CYTOCHROME C RELEASE FROM MITOCHONDRIA
  • ASSAYS FOR CYTOSTATIC OR LONG-TERM IMPACT
    • CLONOGENIC CELL SURVIVAL ASSAY
  • MULTIPLEX ASSAYS
  • COMPOSITE SCREENING STRATEGIES
  • HIGH THROUGHPUT
  • CORRELATION WITH GENE-EXPRESSION DATA
  • TOXICOLOGY AND ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION ASSAYS
  • ACUTE TOXICITY
    • CYTOTOXICITY ASSAY KIT
  • CHRONIC AND REPEATED DOSE TOXICITY
    • SUB-CHRONIC STUDIES
    • ACCUMULATION AND FREQUENCY OF EXPOSURE
    • DOSAGE LEVELS
    • DURATION
    • REVERSIBILITY
    • ANALYSIS
    • DEVELOPMENT OF REPEATED DOSE TOXICITY TESTING IN VITRO
  • CARCINOGENICITY AND GENOTOXICITY
    • IN VITRO METHODS: BACKGROUND AND RECENT DEVELOPMENTS
    • REGULATORY VERSUS DRUG DEVELOPMENT APPLICATIONS
    • AMES TEST
    • IN VITRO MICRONUCLEUS TEST
  • EFFORTS TO REDUCE FALSE POSITIVES
  • RECENT INNOVATIONS FOR SCREENING
    • METABOLITE ASSESSMENT
  • FUTURE CHALLENGE: NON-GENOTOXIC CARCINOGENS
    • REPRODUCTIVE AND DEVELOPMENTAL TOXICITY
    • FOLLOWING THE REPRODUCTIVE CYCLE
    • EMBRYOTOXICITY
    • MALE REPRODUCTIVE TOXICITY
    • FEMALE REPRODUCTIVE TOXICITY
    • DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY TESTING TYPES
    • ZEBRAFISH MODEL FOR DEVELOPMENTAL TOXICITY SCREENING
    • COMBINATIONS OF ZEBRAFISH AND STEM CELLS
    • BIOMEDICAL FRONTIERS: MALE TESTIS
  • ENDOCRINE DISRUPTOR SCREENING
    • ENVIRONMENTAL TOXICOLOGY IMPACTS IN VITRO METHODS
    • U.S. ENVIRONMENTAL PROTECTION AGENCY'S ENDOCRINE DISRUPTOR SCREENING PROGRAM
      • TABLE 19: IN VITRO AND IN VIVO ASSAY TESTS IN THE TIER 1 SCREENING BATTERY, 2013
    • HIGH-PRODUCTION VOLUME CHEMICALS
    • TOXCAST AND TOX 21 INITIATIVES
    • FUTURE CHALLENGE: THYROID DISRUPTION
    • BG1 ASSAY
  • LIVER TOXICITY APPLICATIONS
  • IMPORTANCE OF TWO-DIMENSIONAL VERSUS THREE-DIMENSIONAL SYSTEMS
  • IMMUNE MEDIATED DRUG-INDUCED LIVER INJURY
  • KIDNEY TOXICITY
    • FUTURE CHALLENGE: STEM CELL-DERIVED KIDNEY CELLS
  • ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION AND TOXICOKINETICS
    • IN VITRO DEVELOPMENTS
    • UNMET NEED FOR METABOLIC TRANSFORMATION
    • IN VITRO METABOLISM OFFERINGS
    • METABOLISM BY CYP450 ENZYMES: REACTION PHENOTYPING STUDIES
    • CYPROTEX
  • MICROFLUIDICS AND ORGANS-ON-A-CHIP
  • SUMMARY
  • COMMERCIAL CONSIDERATIONS
    • CELL-BASED ASSAY MARKET
    • GENOME SEQUENCING MARKET
    • MARKET
      • TABLE 20: GLOBAL RESEARCH ASSAYS USED IN METABOLOMICS MARKET, THROUGH 2020 ($ MILLIONS)

CHAPTER 6 - BIOINFORMATICS IN METABOLOMICS

  • OVERVIEW
  • BIOINFORMATIC PROCESSES
    • TABLE 21: BIOINFORMATIC PROCESSES FOR METABOLOMICS
  • DATA COMPOSITION ANALYSIS AND PROCESSING
    • DATA COMPOSITION ANALYSIS
      • XCMS
      • Others
        • TABLE 22: METABOLOMIC OPEN-ACCESS DATA-PROCESSING TOOLS
  • DATA REDUCTION AND INTEGRATION
    • STATISTICAL APPROACHES AND CHALLENGES
    • GENOMICS INFLUENCE
    • METABOLOMIC METHODS
    • PRINCIPAL COMPONENT ANALYSIS
      • Upgrading Principal Component Analysis
    • FUNCTIONAL CLASSIFIERS BASED ON PATHWAYS AND NETWORKS
    • PATHWAY MAPS
    • KNOWLEDGE-BASED APPROACHES
  • DATA MODELING
    • RECONSTRUCTION
    • VERIFICATION
    • NETWORK SIMULATION
  • DATA VISUALIZATION
  • DATABASE CURATION AND MANAGEMENT
  • METABOLOMICS PUBLIC RESOURCES
    • TABLE 23: METABOLOMIC PUBLIC RESOURCES
  • SELECT DESCRIPTIONS
    • DAVID WISHART RESEARCH GROUP
    • METLIN
    • KYOTO ENCYCLOPEDIA OF GENES AND GENOMES
    • OTHERS
      • TABLE 24: OTHER METABOLOMIC BIOINFORMATIC RESOURCES
  • COMMERCIAL MARKET STRUCTURE
    • VENDORS AND EQUIPMENT MANUFACTURERS
    • BIOINFORMATICS COMPANIES AND SYSTEMS BIOLOGY PLAYERS WITH A SPECIFIC FOCUS ON METABOLOMICS RESEARCH
      • Thomson Reuters' Metadrug
    • GENEDATA SCREENER AND EXPRESSIONIST
    • QIAGEN
    • INGENUITY PATHWAY ANALYSIS
    • BMSYSTEMS
  • COMPANIES THAT DEVELOP THEIR OWN SOFTWARE
    • METABOLON
    • CHENOMX
    • LIMITATIONS
    • UNMET NEEDS
    • DATA STANDARDIZATION
  • MARKET
    • TABLE 25: GLOBAL BIOINFORMATIC TOOLS USED IN THE METABOLOMIC MARKET, THROUGH 2020 ($ MILLIONS)

CHAPTER 7 - CLINICAL BIOMARKERS

  • OVERVIEW
    • TABLE 26: MAJOR CLINICAL METABOLOMIC APPLICATIONS
  • BIOMARKER CHALLENGES
  • PROGRESS FROM PROTEOMICS
  • METABOLOMIC ADVANTAGE
  • APPLICATION ADOPTION
    • GENOMICS LEADERSHIP
    • METABOLOMICS' KEY ROLE
  • MAJOR CLINICAL APPLICATIONS
    • INBORN ERRORS OF METABOLISM
    • BACKGROUND
      • Amino Acid Disorders
      • Fatty Acid Oxidation Disorders
      • Organic Acid Disorders
    • ONSET AND SEVERITY
    • EXAMPLES OF INBORN ERRORS OF METABOLISM
    • INCIDENCE AND TESTING
  • PHARMACOGENOMICS
    • PHARMACOGENOMICS ADOPTION
    • CURRENT SUCCESSES IN PHARMACOGENOMICS
      • Warfarin
      • Simvastatin
      • Cancer Drugs
        • Cisplatin Chemotherapy
        • Anthracyclines
  • LIVER ENZYME CYP2C19
  • CLOPIDIGREL
  • CODEINE
  • HUMAN LEUKOCYTE ANTIGEN B
  • CARBAMAZEPINE
  • AZATHIOPRINE
  • MENTAL HEALTH
    • ANTIDEPRESSANTS
  • SEROTONIN
  • CATECHOL METHYL TRANSFERASE
  • PHARMACOKINETIC AND PHARMACODYNAMIC GENES
  • COMMERCIAL EXAMPLE
  • CHALLENGES AND FUTURE DIRECTIONS
    • VALIDATION
  • CANCER
    • CANCER HALLMARKS
    • CANCER METABOLISM OVERVIEW
    • CANCER GLUCOSE METABOLISM
    • CANCER GLUTAMINE METABOLISM
    • CANCER SERINE AND GLYCINE METABOLISM
    • ONE-CARBON METABOLISM
    • CANCER AND THE FOLATE CYCLE
      • Folic Acid
    • METHIONE CYCLE
    • CANCER AND GLUTATHIONE CYCLE
    • LIPID METABOLISM
    • CANCER DRUG APPLICATIONS
      • Folate Agonist Drugs
      • Nucleotide Metabolism
      • Targeting Metabolic Enzymes in Cancer
      • Enzyme Starvation
      • Mitochondrial Folate Metabolism
      • In Vitro Models
      • Path Forward
  • CARDIOVASCULAR AND METABOLIC DISEASE
    • APPLICATIONS
    • PLANNED MYOCARDIAL ISCHEMIA AND INFARCTION
    • EXERCISE STRESS TESTING
    • ALCOHOL SEPTAL ABLATION
    • NITRIC OXIDE METABOLIC PATHWAY
    • ANTHRACYCLINE-INDUCED CARDIOTOXICITY
    • ATRIAL FIBRILLATION
    • DETECTING HEART FAILURE VERSUS B-TYPE NATRIURETIC PEPTIDE
    • PULMONARY HYPERTENSION
      • Pulmonary Hypertension as Mitochondria Dysfunction
      • Pulmonary Hypertension and Insulin Resistance
    • ATHEROSCLEROSIS RISK
      • Lipid Profiles
      • Cholesterol
      • Particles
    • CHOLESTEROL TESTING CLINICAL USES AND MARKET
    • STATINS
    • POSSIBLE ADVERSE DRUG REACTIONS
    • SERUM MARKERS
    • STATIN DOSE MARKER
    • COADMINISTRATION
    • METABOLIZATION DIFFERENCES
    • GENETIC VARIABILITY
    • LIPID PROFILE
    • BEYOND STATINS TO MULTIMARKER APPROACH
      • Jupiter Trial
      • Jupiter Expands Statin Use
      • Jupiter Also Raises Diabetes Risk
      • Guidelines
    • SYSTEMIC AND VASCULAR INFLAMMATION
      • High-Sensitivity C-Reactive Protein
      • Myeloperoxidase
      • Lipoprotein-Associated Phospholipase-A2
    • ADVANCED LIPID TESTING
      • Apolipoprotein B and A1 (ApoA1)
      • Small-Dense LDL
      • Lipoprotein (a)
      • HDL2b
      • Particle Type
    • COMPANIES OFFERING ADVANCED LIPID TESTING
    • LIPOSCALE TEST
    • PRIMARY CARE PHYSICIANS
    • CLEVELAND HEARTLAB
    • NON-FASTING TRIGLYCERIDES
    • METABOLOMIC APPLICATIONS
    • LIPIDOMICS
    • CHOLINE METABOLISM
    • ACYLCARNITINES
      • Trimethylamine N-oxide
    • MICROFLORA-DERIVED CHOLINE METABOLITES
    • LINK WITH GUT MICROFLORA
    • DIABETES AND PRE-DIABETES
      • Insulin Resistance
      • Link with Obesity not Conclusive
    • TOOLS TO DETECT INSULIN RESISTANCE
    • COMPANIES OFFERING INSULIN-RESISTANCE TESTING
    • OTHER INSULIN-RESISTANCE TESTING
      • Branched-Chain Amino Acids: Insulin Resistance via Exercise Stress Testing
      • Branched-Chain Amino Acids and Gastric Bypass
  • LIVER DISEASES
    • METHYLATION DEFICIENCY
    • FOLATE DEFICIENCY
    • CLINICAL LIVER DISEASE
      • Diagnosis
      • Treatment
      • Research
      • Progress on Non-Alcoholic Fatty Liver Disease
      • OWL
      • European Association for the Study of the Liver
    • APPLICATIONS IN LIVER RESEARCH
      • Liver Metabolism Overview
      • Liver Function and Structure
        • Hepatocytes or Parenchymal Cells
        • Specialized Liver Endothelial Cells
        • Non-Parenchymal Stellate and Kupffer Cells
        • Morphogen Signaling
      • In Vitro Applications
      • Drug-Induced Liver Injury
        • Kiyatec
      • Liver Inflammation Models
        • Hepregen
      • Liver Regeneration
        • Achieving Hepatocyte Expansion Still Elusive
        • Cell Types
        • HepaRG
          • TABLE 27: ORGANIZATIONS OFFERING IMMORTALIZED CELL LINES, 2013
      • Human and Other Primary Hepatocytes
        • TABLE 28: COMPANIES OFFERING PRIMARY CELLS, 2013
      • Stem Cell-Derived Hepatocytes
        • RAFT for iPS Hepatocytes Longevity
        • Hepatotoxicity Screening Library
      • Stem Cell Companies
      • TABLE 29: COMPANIES OFFERING STEM CELLS FOR LIVER SAFETY TESTING AND RESEARCH, 2013
    • TOXICITY STUDIES AND NON-PARENCHYMAL CELLS AS DRIVERS OF IN VITRO DEVELOPMENT
    • TYPICAL END POINTS
    • KEY REQUIREMENTS
      • Cell-Cell Contacts Key for Differentiation and Functionality
      • Oxygen Supply
      • Co-Culture
      • Developments
      • Challenges
      • Benefits of Three-Dimensional Spheroids
      • High-Content Imaging and Analysis
      • Microfluidics
        • Dielectrophoretic Forces
        • HepaChip
        • Learnings from Microfluidics
        • Self-Organizing Systems
  • COMMERCIAL CONSIDERATIONS
    • LABORATORY-DEVELOPED TESTS
      • TABLE 30: LABORATORY-DEVELOPED TEST PROVIDERS, 2015
    • CLEVELAND HEARTLAB
    • MARKET
      • TABLE 31: GLOBAL CLINICAL BIOMARKERS USED IN METABOLOMICS MARKET, THROUGH 2020 ($ MILLIONS)

CHAPTER 8 - COMPANY PROFILES

  • ABCAM
  • AGILENT TECHNOLOGIES INC.
  • ATHEROTECH DIAGNOSTICS LAB
  • BG MEDICINE INC.
  • BIOVISION INC.
  • CALITHERA BIOSCIENCES INC.
  • CHENOMX
  • CITOXLAB
  • CLEVELAND HEARTLAB INC.
  • CLINMET INC.
  • COURTAGEN LIFE SCIENCES INC.
  • CYPROTEX PLC
  • EMD MILLIPORE
  • EXALENZ BIOSCIENCE LTD,
  • GENOMIND INC.
  • LECO CORP.
  • LUMINEX CORP.
  • METABOLOMIC DIAGNOSTICS
  • METABOLOMIC TECHNOLOGIES INC.
  • METABOLOMX
  • METABOLON INC.
  • METANOMICS GMBH
  • ONE WAY LIVER GENOMICS, S.L
  • PHENOMENOME DISCOVERIES INC.
  • PROMEGA CORP.
  • QIAGEN GMBH
  • SEAHORSE BIOSCIENCE
  • SIGMA-ALDRICH
  • STEMINA BIOMARKER DISCOVERY INC.
  • THERMO FISHER SCIENTIFIC
  • XENOTECH

LIST OF TABLES

  • SUMMARYTABLE: GLOBAL METABOLOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: HUMAN METABOLOME PROJECT AND DATABASE, 2006-2013
    • TABLE 2: CELLULAR RESPIRATION STAGES
    • TABLE 3: FACTORS IMPACTING ENZYME ACTIVITY
    • TABLE 4: PUBLICATIONS USING KEYWORD METABOLOMICS IN THE SEARCH, 2002-2014 (TOTAL PER YEAR)
    • TABLE 5: TYPICAL ANALYTICAL METRABOLOMIC PROCESS STEPS
    • TABLE 6: MAIN SEPARATION INSTRUMENT SUPPLIERS
    • TABLE 7: MAIN MASS SPECTROSCOPY SUPPLIERS FOR LIFE SCIENCES
    • TABLE 8: LEADING MASS SPECTROSCOPY SYSTEMS
    • TABLE 9: COMMON HYPHENATED PLATFORMS IN METABOLOMIC RESEARCH
    • TABLE 10: GLOBAL MASS SPECTROMETRY MARKET, THROUGH 2017 ($ BILLIONS)
    • TABLE 11: GLOBAL ANALYTICAL EQUIPMENT USED IN THE METABOLOMIC MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 12: HIGH-CONTENT SCREENING SUPPLIERS AND KEY ATTRIBUTES
    • TABLE 13: LABEL-FREE TECHNOLOGIES AND SUPPLIERS
    • TABLE 14: OTHER ASSAY TYPES USED IN METABOLOMIC RESEARCH
    • TABLE 15: MAIN CELL METABOLISM ASSAY APPLICATIONS
    • TABLE 16: ASSAYS COMMONLY USED IN METABOLOMICS
    • TABLE 17: MAJOR CATEGORIES OF ASSAYS USED IN METABOLOMICS FOR DRUG DISCOVERY
    • TABLE 18: OTHER ASSAYS COMMONLY USED ALONGSIDE METABOLOMIC ASSAYS
    • TABLE 19: IN VITRO AND IN VIVO ASSAY TESTS IN THE TIER 1 SCREENING BATTERY, 2013
    • TABLE 20: GLOBAL RESEARCH ASSAYS USED IN METABOLOMICS MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 21: BIOINFORMATIC PROCESSES FOR METABOLOMICS
    • TABLE 22: METABOLOMIC OPEN-ACCESS DATA-PROCESSING TOOLS
    • TABLE 23: METABOLOMIC PUBLIC RESOURCES
    • TABLE 24: OTHER METABOLOMIC BIOINFORMATIC RESOURCES
    • TABLE 25: GLOBAL BIOINFORMATIC TOOLS USED IN THE METABOLOMIC MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 26: MAJOR CLINICAL METABOLOMIC APPLICATIONS
    • TABLE 27: ORGANIZATIONS OFFERING IMMORTALIZED CELL LINES, 2013
    • TABLE 28: COMPANIES OFFERING PRIMARY CELLS, 2013
    • TABLE 29: COMPANIES OFFERING STEM CELLS FOR LIVER SAFETY TESTING AND RESEARCH, 2013
    • TABLE 30: LABORATORY-DEVELOPED TEST PROVIDERS, 2015
    • TABLE 31: GLOBAL CLINICAL BIOMARKERS USED IN METABOLOMICS MARKET, THROUGH 2020 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL METABOLOMIC MARKET BY APPLICATION, 2014-2020 ($ MILLIONS)
    • FIGURE 1: PUBLICATIONS USING KEYWORD METABOLOMICS IN THE SEARCH, 2002-2014 (TOTAL PER YEAR)
Back to Top